home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9605a.zip
/
M9650417.TXT
< prev
next >
Wrap
Text File
|
1996-03-09
|
2KB
|
34 lines
Document 0417
DOCN M9650417
TI A novel, picomolar inhibitor of human immunodeficiency virus type 1
protease.
DT 9605
AU Sham HL; Zhao C; Stewart KD; Betebenner DA; Lin S; Park CH; Kong XP;
Rosenbrook W Jr; Herrin T; Madigan D; Vasavanonda S; Lyons N; Molla A;
Saldivar A; Marsh KC; McDonald E; Wideburg NE; Denissen JF; Robins T;
Kempf DJ; Plattner JJ; Norbeck DW; Pharmaceutical Products Division,
Abbott Laboratories, Abbott; Park, Illinois 60064-3500.
SO J Med Chem. 1996 Jan 19;39(2):392-7. Unique Identifier : AIDSLINE
MED/96145172
AB The design, synthesis, and molecular modeling studies of a novel series
of azacyclic ureas, which are inhibitors of human immunodeficiency virus
type 1 (HIV-1) protease that incorporate different ligands for the S1',
S2, and S2' substrate-binding sites of HIV-1 protease are described. The
synthesis of this series is highly flexible in the sense that the P1',
P2, and P2' residues of the inhibitors can be changed independently.
Molecular modeling studies on the phenyl ring of the P2 and P2' ligand
suggested incorporation of hydrogen-bonding donor/acceptor groups at the
3' and 4-positions of the phenyl ring should increase binding potency.
This led to the discovery of compound 7f (A-98881), which possesses high
potency in the HIV-1 protease inhibition assay and the in vitro MT-4
cell culture assay (Ki = approximately 5 pM and EC50 = 0.002 microM).
This compares well with the symmetrical cyclic urea 1 pioneered at
DuPont Merck.
DE Binding Sites Drug Resistance, Microbial HIV Protease/METABOLISM HIV
Protease Inhibitors/*CHEMICAL SYNTHESIS/*PHARMACOLOGY HIV-1/DRUG
EFFECTS/*ENZYMOLOGY Models, Molecular JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).